MCM
AGIO icon

Moore Capital Management’s Agios Pharmaceuticals AGIO Stock Holding History

Moore Capital Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-150,000
Closed -$4.08M – 640
2025
Q4 		$4.08M Buy
150,000
+95,000
+173% +$3.33M 0.06% 282
2025
Q3 		$2.21M Sell
55,000
-25,000
-31% -$940K 0.03% 348
2025
Q2 		$2.66M Buy
80,000
+20,000
+33% +$606K 0.03% 290
2025
Q1 		$1.76M Hold
60,000
– – 0.04% 277
2024
Q4 		$1.97M Sell
60,000
-40,000
-40% -$1.88M 0.02% 332
2024
Q3 		$4.44M Buy
100,000
+40,000
+67% +$1.82M 0.08% 235
2024
Q2 		$2.59M Buy
+60,000
New +$2.17M 0.04% 254

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Moore Capital Management's AGIO Position: Q1 2026 in Review

Moore Capital Management sold out of Agios Pharmaceuticals (AGIO) in Q1 2026, closing a stake of 150,000 shares — an estimated $4.08M sold.

Moore Capital Management first reported a position in AGIO in Q2 2024 and held it in 7 quarters. The position peaked at $4.44M in Q3 2024. 234 funds tracked by Wall St. Rank hold AGIO as of Q1 2026.

  • Moore Capital Management reported no remaining Agios Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Moore Capital Management sold 150,000 Agios Pharmaceuticals shares in Q1 2026, an estimated $4.08M.
  • Moore Capital Management first reported a position in Agios Pharmaceuticals in Q2 2024 and held it in 7 quarters.
  • Moore Capital Management's Agios Pharmaceuticals position peaked at $4.44M in Q3 2024.
  • 234 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2026.

Based on Moore Capital Management's 13F filing for Q1 2026, filed 15 May 2026.